Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

11130	Companies
245133	Keywords
173220	Articles
132229	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 06/17/2025 at 07:55, 1 year 3 months ago

EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
Formycon AG plans EUR 50 million senior unsecured bond issuance for company growth. Joint Lead Managers: IKB Deutsche Industriebank AG, Pareto Securities AS

Formycon AG Bond Issuance EUR 50 Million Senior Unsecured Joint Lead Managers
BRIEF

published on 06/05/2025 at 06:35, 1 year 4 months ago

Le biosimilaire Lucentis® FYB201/Ranivisio® obtient l'approbation au Brésil

Formycon AG Maladies De La Rétine Lucentis® Biosimilaire Approbation Du Brésil Partenariat Biomm
BRIEF

published on 06/05/2025 at 06:35, 1 year 4 months ago

Lucentis® Biosimilar FYB201/Ranivisio® Gains Approval in Brazil

Formycon AG Retinal Diseases Lucentis® Biosimilar Brazil Approval Biomm Partnership
PRESS RELEASE

published on 06/05/2025 at 06:30, 1 year 4 months ago

Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Brazil approves Formycon AG's Lucentis biosimilar FYB201/Ranivisio, marking the beginning of Latin America rollout. Commercial partnership with Biomm established

Formycon AG Lucentis Biosimilar Brazil Approval Biomm Partnership Market Rollout
BRIEF

published on 05/27/2025 at 14:35, 1 year 4 months ago

Formycon et Fresenius Kabi lancent Otulfi™ au Canada

Marché Canadien Soutien Aux Patients Biosimilaire De L'ustekinumab Maladies Auto-immunes Chroniques Thérapies Biologiques
BRIEF

published on 05/27/2025 at 14:35, 1 year 4 months ago

Formycon and Fresenius Kabi Launch Otulfi™ in Canada

Canadian Market Patient Support Ustekinumab Biosimilar Chronic Autoimmune Diseases Biologic Therapies
PRESS RELEASE

published on 05/27/2025 at 14:30, 1 year 4 months ago

Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases

Canada Formycon Fresenius Kabi Ustekinumab Biosimilar FYB202/Otulfi
BRIEF

published on 05/19/2025 at 15:05, 1 year 4 months ago

Formycon and Fresenius Kabi Achieve FDA Interchangeability Approval for FYB202/Otulfi®

FDA Approval Biosimilars Formycon Fresenius Kabi Otulfi®
BRIEF

published on 05/19/2025 at 15:05, 1 year 4 months ago

Formycon et Fresenius Kabi obtiennent l'approbation d'interchangeabilité de la FDA pour FYB202/Otulfi®

Approbation De La FDA Formycon Fresenius Kabi Biosimilaires Otulfi®
PRESS RELEASE

published on 05/19/2025 at 15:00, 1 year 4 months ago

Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US

FDA Approval Formycon Fresenius Kabi Biologics Interchangeability

Accesswire

Published on 10/05/2026 at 22:30, 10 hours 2 minutes ago

EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 17 hours 47 minutes ago

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 18 hours 2 minutes ago

Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 18 hours 2 minutes ago

Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 18 hours 32 minutes ago

Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth

View all ACCESSWIRE

EQS Group

Published on 10/06/2026 at 08:25, 6 minutes ago

Turnitin Now Offers AI Writing Detection for German, Dutch, and Turkish Language Submissions
Published on 10/06/2026 at 08:20, 11 minutes ago

Smart Payment Association Warns of Growing Supply Chain Pressures on Payment Card Industry
Published on 10/06/2026 at 08:20, 11 minutes ago

MTCM Launches Talea DRN: One Private-Market-Note, Two Rails, for Arrangers and Investors, with Bank Frick as Digital-Asset-Partner and Paying-Agent
Published on 10/06/2026 at 08:05, 26 minutes ago

LX Pantos Holds Completion Ceremony for Katowice Logistics Center in Poland
Published on 10/06/2026 at 08:05, 26 minutes ago

NAS Real Investment Management GmbH Selects Yardi's Connected Real Estate Platform for Commercial Portfolio

Les Echos

Published on 10/05/2026 at 22:12, 10 hours 19 minutes ago

AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 10 hours 19 minutes ago

AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 14 hours 19 minutes ago

Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 14 hours 19 minutes ago

Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 14 hours 32 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026

View all LES ECHOS COMFI WIRE